


In the Claims

1 (original). A peptidomimetic having the structure shown in formula I:



(I)

wherein

R<sup>1</sup> is selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, or heterocycloalkoxycarbonyl, any of which can be optionally substituted with one or more of the following: any halogen, -CN, -COOH, =O, -OH, -NO<sub>2</sub>, -NH<sub>2</sub>, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, and heterocycloalkoxycarbonyl;

or a salt thereof.

2 (original). The peptidomimetic according to claim 1, wherein R<sup>1</sup> is aryl optionally substituted with one or more halogen, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -CH<sub>3</sub>, or -OCH<sub>3</sub>.

3 (original). The peptidomimetic according to claim 2, wherein said one or more halogen is, independently, Cl or F.


4 (original). The peptidomimetic according to claim 1, wherein R<sup>1</sup> is phenyl substituted with one or more halogen, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -CH<sub>3</sub>, or -OCH<sub>3</sub>.

5 (original). The peptidomimetic according to claim 4, wherein said one or more halogen is, independently, Cl or F.


6 (original). The peptidomimetic according to claim 1, wherein R<sup>1</sup> is heteroaryl optionally substituted with one or more halogen, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -CH<sub>3</sub>, or -OCH<sub>3</sub>.

7 (original). The peptidomimetic according to claim 6, wherein said one or more halogen is, independently, Cl or F.


8 (original). The peptidomimetic according to claim 1, selected from the group consisting of:



or




or




;

or




;

or




;

or




;

or




;

or




;


or




or



or




or







or



or




or




;

or



;


and




9 (original). A composition comprising a peptidomimetic of claim 1 in a pharmaceutically acceptable carrier or diluent.

10 (currently amended). A method for inhibiting growth or replication, or inducing apoptosis in a target cell, said method comprising contacting the target cell with a peptidomimetic of claim 1 or a composition of claim 9.


11 (original). The method according to claim 10, wherein said peptidomimetic is selected from the group consisting of:



or




or




;

or




;

or




;

or




;


or



or




or



;


or



;




or




;

or




;


or



or




or




;

or




;

and




12 (currently amended). A method for treating a tumor or an oncological disorder in a human or animal, said method comprising administering an effective amount of a peptidomimetic of claim 1 or a composition of claim 9 to the human or animal.


13 (original). The method according to claim 12, wherein said peptidomimetic is selected from the group consisting of:



or




or




;

or




;

or




;

or




;

or




or






or




;

or




;

or




;

or




;


or



or




or




;

or




;

and



14 (original). The method according to claim 12, wherein said tumor or oncological disorder is selected from the group consisting of breast, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, colon, ovary, lung, bladder, skin, muscle, pancreas, prostate, bone, eye, blood cells, and brain.

15 (original). A peptidomimetic having the formula:



wherein

$R^1$  is selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl, alkoxy carbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, heterocycloalkoxy, or heterocycloalkoxy carbonyl, any of which can be optionally substituted with one or more of the following: any halogen, -CN, -COOH, =O, -OH, -NO<sub>2</sub>, -NH<sub>2</sub>, -N-alkyl, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkylcarbonyl,

alkoxycarbonyl, cycloalkylcarbonyl, heteroalkyl, heterocycloalkyl, heterocycloalkylcarbonyl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocycloalkoxy, and heterocycloalkoxycarbonyl;


Y\* is phosphotyrosine, or any analog thereof;

L is leucine, or another non-polar amino acid;


or a salt thereof.

16 (original). The peptidomimetic according to claim 15, wherein L is alanine or valine.

17 (new). The peptidomimetic according to claim 1, wherein the peptidomimetic has the structure:



18 (new). The method according to claim 10, wherein the peptidomimetic has the structure:



19 (new). The method according to claim 12, wherein the peptidomimetic has the structure:

